Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Acclaimed celebrity eyelash booster now available from Medical Specialists®
  • USA - English


News provided by

Medical Specialists® Pharmacy

Mar 03, 2015, 07:40 ET

Share this article

Share toX

Share this article

Share toX

Online Doctor and Pharmacy
Online Doctor and Pharmacy

Medical Specialists® Pharmacy are delighted to announce Lumigan eye drops are now available to patients who want to grow longer and more luscious eyelashes. No longer will only the famous celebrities be able to afford the product...

Post this

Bury, Lancashire (PRWEB UK) 3 March 2015 -- In the past, women wanting longer, thicker more prominent eyelashes were probably put off by the high prices charged from certain websites for the wildly popular treatments Lumigan or Latisse. These products are so effective in fact that there are countless celebrity users and endorsers that include Brooke Shields, Claire Danes, Helen Mirren, Jenny McCarthy and Mandy Moore, to name just a few, and millions more around the world have been desperate to get their hands on the products in order to have boosted eyelashes just like their favourite celebrities.

In fact, even The Telegraph published part of an interview with Academy Award winning actress Helen Mirren last year, where she praised Latisse. She said: “Quite honestly. I don't really know what a beauty routine is. But I love beauty products, and I'm always trying new ones. One thing I consistently use is Latisse. It really works, and if your eyelashes look great, you can let a lot of other things be cr*p.”

Moreover, Danielle Lineker, model and wife of football legend Gary Lineker, offered beauty tips to The Mirror back in 2011 and spoke of the wonders of the eyelash booster. She commented: “This stuff really works!...It contains prostaglandin analogue that stimulates the eyelash follicles to grow hairs that are much longer, thicker and darker. I’ve had amazing results.”

Here is the great news…Medical Specialists® Pharmacy are pleased to announce Lumigan eye drops are now available to patients who want to grow longer and more luscious eyelashes. No longer will only the famous celebrities be able to afford the product, as Medical Specialists® - famous for its low prices – now offer eyelash booster Lumigan for the rock bottom price of just £49.95…Much more affordable than the £180 - £200 a bottle charged from other websites! It can be obtained either by an online consultation with one of the Medical Specialists® GMC-registered doctors, who will write a private prescription, or via a private prescription from a patient's own doctor.

And to think this all started by pure chance. Back in the early 2000s people suffering with raised pressure in the eye, for example in open-angle glaucoma, were starting to be prescribed the eye-drop solution Lumigan. The ingredient in Lumigan – bimatoprost - works by decreasing pressure inside the eye by increasing the drainage of fluid from the eye into the blood stream. Soon though, it was apparent there were some rather unexpected benefits from the drug.

During this period, eye doctors and their glaucoma patients began to notice one particular side-effect: longer, thicker, darker eyelashes were flourishing over time.

In disbelief at their wonderful finding, Allergan, the makers of the drug, didn’t hesitate to get Lumigan through the necessary clinical trials. Instead of focusing on glaucoma, they were now assessing the impact of Lumigan for a condition known as hypotrichosis - abnormally underdeveloped eyelashes or not sufficient to give you adequate or enough eyelashes.

Following FDA approval in 2008, the product was then launched with the name ‘Latisse’ and promptly marketed for its ground-breaking eyelash-boosting powers. After all, many women believe that longer and lusher eyelashes give them bigger and more appealing eyes.

In respect of eyelash growth, bimatoprost, a synthetic analogue (mimic) of a naturally occurring chemical called prostaglandin, is also believed to be associated with hair growth, working to increase the length of the active hair growth phase.

You might be forgiven for being confused about Lumigan and the American branded version Latisse, and what differences there are – if any. The ingredients, concentrations of all the ingredients, and even the bottled it is supplied in, are all exactly the same. The only thing that separates the two is the packaging and the fact that Latisse is supplied with applicators.

Lumigan may have been first intended to treat glaucoma, but it is far from being the first occasion when a treatment developed with the intention of fighting a disease was later discovered to have other surprising side effects. Cosmetic Botox (also produced by Allergan) was initially used by ophthalmologists to suppress eyelid spasms, whilst Minoxidil (contained in hair loss treatment Regaine) was firstly used as an oral treatment for high blood pressure.

David Bailey, Medical Specialists® Pharmacy, http://www.medical-specialists.co.uk, +44 161 762 9108, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.